Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

Abstract:

:Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resistance with alkylating agents used in MM patients. Based on these considerations, we proposed a phase I/II study testing escalating doses of bendamustine and lenalidomide and fixed low doses of dexamethasone (BdL). Fifteen patients were enrolled in phase I study. Maximum tolerated dose was established at dose "level 0": bendamustine 40 mg/m2 days 1,2; lenalidomide 10 mg days 1-21; d 40 mg days 1,8,15,22 every 28-day cycle, for six cycles. We enrolled 23 patients in the phase II study. BdL combination showed mainly hematological toxicities, fever and infections. Overall response rate was 47%. After median follow up of 22 months, median PFS was 10 months. Two-years OS rate was 65%. BdL combination confirmed to be a promising treatment for patients with relapsed/refractory MM.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Pozzi S,Gentile M,Sacchi S,Marcheselli R,Corso A,Cocito F,Musto P,Guarini A,Minoia C,Vincelli I,Ria R,Rivolti E,Mele G,Bari A,Mazzone C,Badiali S,Marcheselli L,Palumbo A,Morabito F

doi

10.1080/10428194.2016.1205741

subject

Has Abstract

pub_date

2017-03-01 00:00:00

pages

552-559

issue

3

eissn

1042-8194

issn

1029-2403

journal_volume

58

pub_type

杂志文章
  • Transient abnormal myelopoiesis in Down's syndrome.

    abstract::Recent data have elucidated the pathogenesis of transient abnormal myelopoiesis (TAM) to a great extent. TAM is a monoclonal disorder which resolves spontaneously and the target cell in this disorder is a multipotent stem cell which is capable of differentiating into megakaryocytes. The pathogeneses of TAM/AMKL (acute...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209051029

    authors: Kurahashi H,Hara J,Yumura-Yagi K,Tawa A,Kawa-Ha K

    更新日期:1992-12-01 00:00:00

  • Primary breast lymphoma: outcome of 7 patients and a review of the literature.

    abstract::Primary breast lymphomas (PBL) are uncommon neoplasms. Seven PBL were diagnosed between March 1993 and October 2002. A lumpectomy (n=4) or radical mastectomy (n=3) was performed; 5 patients were in clinical stage (CS) II and 2 in CS IV; 6 patients received the CEOP regimen (cyclophosphamide, vincristine, epirubicin an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190500126083

    authors: Vigliotti ML,Dell'olio M,La Sala A,Di Renzo N

    更新日期:2005-09-01 00:00:00

  • Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.

    abstract::Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1375107

    authors: Cummins KD,Gill S

    更新日期:2018-07-01 00:00:00

  • Long noncoding RNA LINC00467 facilitates the progression of acute myeloid leukemia by targeting the miR-339/SKI pathway.

    abstract::A growing body of evidence indicates that long non-coding RNA (lncRNA) is involved in the development and progression of many diseases. It has been reported that lncRNA LINC00467 is disregulated in multiple tumors, while its role in acute myeloid leukemia (AML) is still unknown. Here, we find that LINC00467 expression...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1832667

    authors: Lu J,Wu X,Wang L,Li T,Sun L

    更新日期:2020-10-15 00:00:00

  • Genomic stratification of multiple myeloma treated with novel agents.

    abstract::Cytogenetic testing is now routinely performed for the prognostic work-up of multiple myeloma (MM). The abnormalities del(17p), t(4;14) and del(13q) have been established as predictors of poor outcome in patients with MM treated with conventional chemotherapy or stem cell transplant; chromosome 1q gains and 1p losses ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.608449

    authors: Jiang A,Reece D,Chang H

    更新日期:2012-02-01 00:00:00

  • The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.

    abstract::The purpose of this study was to explore the characteristics and functions of BH3-only proteins Puma, Noxa and Bim in the prognosis, therapy and drug resistance of chronic lymphocytic leukemia (CLL). Puma, Noxa and Bim mRNAs were evaluated by real-time quantitative reverse transcriptase-polymerase chain reaction, and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.787613

    authors: Zhu HJ,Liu L,Fan L,Zhang LN,Fang C,Zou ZJ,Li JY,Xu W

    更新日期:2013-12-01 00:00:00

  • The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML).

    abstract::Immune mechanisms superimposed to the myeloablative conditioning regimens exert an additional powerful effect in eradicating leukemia and in achieving immunological control of minimal residual disease. The impact of GVHD-independent GVL has been evaluated to be absent, or near absent, in ALL, about 30% in AML and abou...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309047890

    authors: Marmont AM

    更新日期:1993-01-01 00:00:00

  • Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.

    abstract::Fludarabine is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM) and its combination with cyclophosphamide has been effective in many patients with low-grade lymphoma and chronic lymphocytic leukemia. Based on these data, we administered the combination of fludarabine (25 mg/m2 i.v. day 1-3) an...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819031000077025

    authors: Dimopoulos MA,Hamilos G,Efstathiou E,Siapkaras I,Matsouka C,Gika D,Grigoraki V,Papadimitriou C,Mitsibounas D,Anagnostopoulos N

    更新日期:2003-06-01 00:00:00

  • Study of specific genetic and epigenetic variables in multiple myeloma.

    abstract::Few studies have examined the association between methylenetetrahydrofolate reductase (MTHFR) SNPs, epigenetic changes, and multiple myeloma (MM). We wished to determine genotype distributions for MTHFR 1298AC SNP in cases of MM and healthy controls and to examine whether there is any correlation between the methylati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.528095

    authors: Hatzimichael E,Dasoula A,Benetatos L,Syed N,Dranitsaris G,Crook T,Bourantas K

    更新日期:2010-12-01 00:00:00

  • R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients.

    abstract::Treatment of diffuse large B-cell lymphoma (DLBCL) with R-CHOP(-like) regimens include large cumulative doses of prednisolone. In this retrospective study, we evaluated changes in vertebral bone density (VD) in DLBCL patients by measuring CT-ascertained Hounsfield units (HU) at the L3 level. In total, 111 patients dia...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1233543

    authors: Svendsen P,Shekhrajka N,Nielsen KL,Vestergaard P,Poulsen MØ,Vistisen AK,Munksgaard PS,Severinsen MT,Jensen P,Johnsen HE,Jakobsen LH,Bøgsted M,Frøkjær JB,El-Galaly TC

    更新日期:2017-05-01 00:00:00

  • Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures.

    abstract:UNLABELLED:We retrospectively analyzed the incidence of thrombotic and infectious complications in relation with the use of central venous catheters (CVCs), in a series of patients with hematological malignancies and low platelet and leucocyte counts. PATIENTS AND METHODS:126 patients with hematological malignancies w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190309178770

    authors: Cortelezzia A,Fracchiolla NS,Maisonneuve P,Moia M,Luchesini C,Ranzi ML,Monni P,Pasquini MC,Lambertenghi-Deliliers G

    更新日期:2003-09-01 00:00:00

  • Treatment of multiple myeloma in the elderly: realities and hopes.

    abstract::Until recently, combination chemotherapy with melphalan and prednisone (MP) has remained the most widely accepted treatment option for elderly patients with multiple myeloma (MM). However, since the availability of new and more active drugs, several groups have compared in several phase III trials the efficacy and saf...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2010.530361

    authors: De La Rubia J,Sanz MA

    更新日期:2011-01-01 00:00:00

  • Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia.

    abstract::The Italian Registry for hairy cell leukemia (HCL) has recorded 725 patients with HCL diagnosed over 25 years. We analysed this large series of patients with the aim of providing an evaluation of changes in clinical presentation, impact of initial therapy and modifications in prognostic factors over the period of two ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,评审

    doi:10.3109/10428199409056295

    authors: Frassoldati A,Lamparelli T,Federico M,Annino L,Capnist G,Pagnucco G,Dini E,Resegotti L,Damasio EE,Silingardi V

    更新日期:1994-04-01 00:00:00

  • Advances in umbilical cord blood transplant: a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013.

    abstract::The 11th International Cord Blood Symposium was devoted to advances in umbilical cord blood (UCB) research and transplant. Results of cord blood transplant (UCB SCT) for congenital storage disease and hemoglobinopathies are encouraging, but UCB SCT may also be useful for older adults with hematologic malignancies, and...

    journal_title:Leukemia & lymphoma

    pub_type:

    doi:10.3109/10428194.2013.837162

    authors: van Besien K

    更新日期:2014-08-01 00:00:00

  • The role of FAS-mediated apoptosis in chronic myelogenous leukemia.

    abstract::Clinical observation and laboratory evidence suggest that immune mechanisms play an important role in the natural control of evolution of the Ph+ clone in chronic phase as well as during progression of chronic myelogenous leukemia (CML). The understanding of these mechanisms could facilitate development of innovative ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009089429

    authors: Selleri C,Maciejewski JP

    更新日期:2000-04-01 00:00:00

  • Psychosocial life achievements in adults even if they received prophylactic cranial irradiation for acute lymphoblastic leukemia during childhood.

    abstract::The aim of this study was to assess life goal achievements in long-term survivors (LTS) receiving cranial radiotherapy (CRT) as central nervous system (CNS) prophylaxis for acute lymphoblastic leukemia (ALL) during childhood, compared to healthy individuals. Participants in this study were 141 LTS treated in our cente...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.710903

    authors: Pillon M,Tridello G,Boaro MP,Messina C,Putti MC,Varotto S,Petris MG,Scrimin S,Zanesco L,Rosolen A,Basso G

    更新日期:2013-02-01 00:00:00

  • Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.

    abstract::Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis. This study retrospectively analyzed patients with AITL from a single institution in Taiwan, aiming to define the clinical features and prognostic factors. Patients with AITL treated at our instituti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.525270

    authors: Lin HN,Liu CY,Hong YC,Pai JT,Yang CF,Yu YB,Hsiao LT,Chiou TJ,Liu JH,Gau JP,Tzeng CH,Chen PM

    更新日期:2010-12-01 00:00:00

  • Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment.

    abstract::We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1131273

    authors: Bekos C,Perkmann T,Krauth M,Raderer M,Lechner K,Jaeger U

    更新日期:2016-09-01 00:00:00

  • Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.

    abstract::Relative risks of treatment-emergent adverse events (TEAEs) and related hospitalization is most accurate when accounting for treatment exposure. AZA-AML-001 showed azacitidine (AZA) prolonged overall survival versus conventional care regimens (CCR) in older patients (≥65 years) with acute myeloid leukemia (AML) by 3.9...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/10428194.2016.1243680

    authors: Seymour JF,Döhner H,Minden MD,Stone R,Gambini D,Dougherty D,Beach CL,Weaver J,Dombret H

    更新日期:2017-06-01 00:00:00

  • Tocilizumab for steroid refractory acute graft-versus-host disease.

    abstract::Acute graft-versus-host-disease (aGVHD) is a frequent and often lethal complication of allogeneic hematopoietic stem cell transplant despite prophylaxis. Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody that has evidence of activity in patients with steroid refractory (SR) GVHD. We retrospectively rep...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1045896

    authors: Roddy JV,Haverkos BM,McBride A,Leininger KM,Jaglowski S,Penza S,Klisovic R,Blum W,Vasu S,Hofmeister CC,Benson DM,Andritsos LA,Devine SM,Efebera YA

    更新日期:2016-01-01 00:00:00

  • The role of interleukin-3 in classical Hodgkin's disease.

    abstract::Classical Hodgkin's disease (HD) is a peculiar form of lymphoma characterized by a low frequency of tumor cells, the so-called Hodgkin (H) and Reed/Sternberg (RS) cells, embedded in a background of non-neoplastic (reactive) cells believed to be recruited and activated by H-RS cell-derived cytokines/chemokines. How the...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400013712

    authors: Aldinucci D,Olivo K,Lorenzon D,Poletto D,Gloghini A,Carbone A,Pinto A

    更新日期:2005-03-01 00:00:00

  • Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.

    abstract::In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or lose response to imatinib, with or without previous interferon treatment...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.578310

    authors: Bengió RM,Riva ME,Moiraghi B,Lanari E,Milone J,Ventriglia V,Bullorsky E,Tezanos Pinto Md,Murro H,Bianchini M,Larripa I

    更新日期:2011-09-01 00:00:00

  • Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cells.

    abstract::We have studied the functional properties of topoisomerase II (Topo II) in a subclone of the HL-60 cell line, which is highly resistant to cytotoxic Topo II inhibitors, but does not express p-glycoprotein. The cells contain the two forms of human topo II with Mr 170 and 180 kDa in equal proportions. Two different stat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148538

    authors: Boege F,Gieseler F,Biersack H,Meyer P

    更新日期:1993-03-01 00:00:00

  • Central Nervous System (CNS) Involvement in Acute Nonlymphocytic Leukemia (ANLL).

    abstract::The incidence of central nervous system (CNS) involvement and effects of therapy were reviewed in 42 consecutive pediatric patients with acute nonlymphocytic leukemia (ANLL). The morphology of ileukemic cells was considered M1 in 13, M2 in 7, M3 in 5, M4 in 8, and M5 in 9. Two patients with M5 morphology presented wit...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009042513

    authors: Barrios N,Tebbi CK,Freeman AI

    更新日期:1990-01-01 00:00:00

  • Comparison of complication rates of Hickman(®) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy.

    abstract::Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.742520

    authors: Lim MY,Al-Kali A,Ashrani AA,Begna KH,Elliott MA,Hogan WJ,Hook CC,Kaufmann SH,Letendre L,Litzow MR,Patnaik MS,Pardanani A,Tefferi A,Wolanskyj AP,Grill DE,Pruthi RK

    更新日期:2013-06-01 00:00:00

  • Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood.

    abstract::Anthracyclines have contributed significantly to the increased cure rate in pediatric oncology. Cardiac toxicity is an important late effect after anthracycline treatment and is thought to occur by reactive oxygen species mediated cardiac damage. We hypothesized that deactivating variants of superoxide dismutase II (S...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190903177212

    authors: Rajić V,Aplenc R,Debeljak M,Prestor VV,Karas-Kuzelicki N,Mlinaric-Rascan I,Jazbec J

    更新日期:2009-10-01 00:00:00

  • Regulation of hematopoiesis by microvascular endothelium.

    abstract::The bone marrow microenvironment is a complex three dimensional structure where hematopoietic stem cells proliferate, mature, migrate into the sinusoidal space, and enter the circulation in an exquisitely regulated fashion. Stromal cells within the BM microenvironment provide a suitable environment for self-renewal, p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709058305

    authors: Rafii S,Mohle R,Shapiro F,Frey BM,Moore MA

    更新日期:1997-11-01 00:00:00

  • Transition of polycythemia vera to chronic neutrophilic leukemia.

    abstract::Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909093744

    authors: Higuchi T,Oba R,Endo M,Harada H,Mori H,Niikura H,Omine M,Fujita K

    更新日期:1999-03-01 00:00:00

  • Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.

    abstract::Survival of chronic lymphocytic leukemia (CLL) cells in vivo is supported by the tissue microenvironment, which includes components of the extracellular matrix. Interactions between tumor cells and the extracellular matrix are in part mediated by CD44, whose principal ligand is hyaluronic acid. Here, we show that CD44...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.569962

    authors: Herishanu Y,Gibellini F,Njuguna N,Hazan-Halevy I,Farooqui M,Bern S,Keyvanfar K,Lee E,Wilson W,Wiestner A

    更新日期:2011-09-01 00:00:00

  • Detection of residual disease in acute lymphoblastic leukemia of childhood.

    abstract::Several techniques developed in recent years provide us with the capability to detect sub-microscopic leukemia during remission. Quantitative polymerase chain reaction (PCR) is thus far the most sensitive assay that is applicable in most patients with acute lymphoblastic leukemia (ALL) of childhood. However, false-pos...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909093724

    authors: Estrov Z,Freedman MH

    更新日期:1999-03-01 00:00:00